First Header Logo Second Header Logo

Connection

Ashish Khanna to Shock

This is a "connection" page, showing publications Ashish Khanna has written about Shock.
Connection Strength

5.596
  1. Kotani Y, Landoni G, Belletti A, Khanna AK. Response to: norepinephrine formulation for equivalent vasopressive score. Crit Care. 2023 Mar 28; 27(1):125.
    View in: PubMed
    Score: 0.888
  2. Kotani Y, Di Gioia A, Landoni G, Belletti A, Khanna AK. An updated "norepinephrine equivalent" score in intensive care as a marker of shock severity. Crit Care. 2023 Jan 20; 27(1):29.
    View in: PubMed
    Score: 0.877
  3. Wieruszewski PM, Khanna AK. Vasopressor Choice and Timing in Vasodilatory Shock. Crit Care. 2022 03 22; 26(1):76.
    View in: PubMed
    Score: 0.828
  4. Wakefield BJ, Busse LW, Khanna AK. Angiotensin II in Vasodilatory Shock. Crit Care Clin. 2019 Apr; 35(2):229-245.
    View in: PubMed
    Score: 0.665
  5. Khanna A, Ostermann M, Bellomo R. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 12 28; 377(26):2604.
    View in: PubMed
    Score: 0.617
  6. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 08 03; 377(5):419-430.
    View in: PubMed
    Score: 0.592
  7. Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, Deane AM, Ostermann M, Wunderink RG, Boldt DW, Kroll S, Greenfeld CR, Hodges T, Chow JH. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023 May 05; 27(1):175.
    View in: PubMed
    Score: 0.224
  8. Bansal M, Mehta A, Wieruszewski PM, Belford PM, Zhao DX, Khanna AK, Vallabhajosyula S. Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review. Am J Emerg Med. 2023 Apr; 66:124-128.
    View in: PubMed
    Score: 0.220
  9. Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, Hästbacka J, Khanna AK, Albertson TE, Tumlin J, Storey K, Handisides D, Tidmarsh GF, Chawla LS, Ostermann M. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial. Am J Respir Crit Care Med. 2020 11 01; 202(9):1253-1261.
    View in: PubMed
    Score: 0.188
  10. Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, Khanna AK, McCurdy MT, Ostermann M, Young PJ, Handisides DR, Chawla LS, Tidmarsh GF, Albertson TE. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020 02 06; 24(1):43.
    View in: PubMed
    Score: 0.179
  11. Abril MK, Khanna AK, Kroll S, McNamara C, Handisides D, Busse LW. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data. J Crit Care. 2019 04; 50:188-194.
    View in: PubMed
    Score: 0.165
  12. Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of Refractory Vasodilatory Shock. Chest. 2018 08; 154(2):416-426.
    View in: PubMed
    Score: 0.155
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.